- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 21, 2022
Highlights
- Market Cap
- $1.03M
- Enterprise Value
- -$1.58M
- EPS (TTM)
- -$2.57
- Total Revenue (TTM)
- $87.86K
- Gross Profit (TTM)
- -$228.41K
- EBITDA (TTM)
- -$12.00M
- Year Range
- $0.10 - $1.14
- ROA (TTM)
- -213.89%
- ROE (TTM)
- -230.12%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VRAX Performance Chart
Virax Biolabs Group Limited (VRAX) is down 37.5% since the beginning of the year. At $0 per share, VRAX is trading 81.0% below its 52-week high of $1.
Loading charts...
Returns By Period
Virax Biolabs Group Limited (VRAX) has returned -37.45% so far this year and -77.93% over the past 12 months.
Virax Biolabs Group Limited
- 1D
- 20.97%
- 1M
- 64.11%
- YTD
- -37.45%
- 6M
- -44.95%
- 1Y
- -77.93%
- 3Y*
- -62.03%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
VRAX Monthly Returns History
Based on dividend-adjusted daily data since Jul 21, 2022, VRAX's average daily return is -0.10%, while the average monthly return is -5.84%.
Historically, 29% of months were positive and 71% were negative. The best month was Aug 2024 with a return of +274.3%, while the worst month was Jul 2022 at -70.3%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.
On a daily basis, VRAX closed higher 41% of trading days. The best single day was Aug 19, 2024 with a return of +141.8%, while the worst single day was Jul 29, 2022 at -74.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -18.16% | -19.54% | -3.43% | -39.11% | 41.22% | 14.38% | -37.45% | ||||||
| 2025 | -24.89% | -1.18% | -31.74% | -14.02% | -1.81% | -17.75% | 2.32% | -25.22% | 0.38% | -7.58% | -28.36% | -14.11% | -84.63% |
| 2024 | -43.84% | 17.38% | -25.51% | -12.13% | 87.30% | -1.69% | 7.33% | 274.30% | -58.37% | 6.70% | -4.83% | 14.21% | 54.11% |
| 2023 | 3.84% | -10.17% | 2.13% | -39.89% | -6.29% | -0.46% | 1.72% | -9.73% | -9.22% | -24.52% | -5.22% | -37.20% | -80.00% |
| 2022 | -70.33% | -35.00% | -10.26% | -52.06% | 3.64% | -53.35% | -95.99% |
Benchmark Metrics
Virax Biolabs Group Limited has an annualized alpha of -34.11%, beta of 0.92, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 22, 2022.
- This stock participated in 262.97% of S&P 500 Index downside but only -138.66% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -34.11%
- Beta
- 0.92
- R²
- 0.01
- Upside Capture
- -138.66%
- Downside Capture
- 262.97%
Return for Risk
Risk / Return Rank
VRAX ranks 14 for risk / return — in the bottom 14% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Virax Biolabs Group Limited (VRAX) and compare them to S&P 500 Index.
| VRAX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.51 | 2.39 | -2.90 |
Sortino ratioReturn per unit of downside risk | -0.72 | 3.25 | -3.98 |
Omega ratioGain probability vs. loss probability | 0.92 | 1.43 | -0.51 |
Calmar ratioReturn relative to maximum drawdown | -0.86 | 3.11 | -3.97 |
Martin ratioReturn relative to average drawdown | -1.27 | 14.38 | -15.65 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Virax Biolabs Group Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Virax Biolabs Group Limited was 99.95%, occurring on Apr 10, 2026. The portfolio has not yet recovered.
The current Virax Biolabs Group Limited drawdown is 99.90%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.95%Apr 2026 | 3y 8mo | — | 3y 10moJul 2022 - now |
Bear market2022 | -43.19%Jul 2022 | 0s | 4d | 4dJul 2022 - Jul 2022 |
Drawdown Indicators
| VRAX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.95% | -56.78% | -43.17% |
Max Drawdown (1Y)Largest decline over 1 year | -90.62% | -9.10% | -81.52% |
Max Drawdown (3Y)Largest decline over 3 years | -98.37% | -18.90% | -79.47% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.90% | 0.00% | -99.90% |
Average DrawdownAverage peak-to-trough decline | -97.04% | -10.72% | -86.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 61.41% | 1.97% | +59.44% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Virax Biolabs Group Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Virax Biolabs Group Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VRAX relative to other companies in the Biotechnology industry. Currently, VRAX has a P/S ratio of 11.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VRAX in comparison with other companies in the Biotechnology industry. Currently, VRAX has a P/B value of 0.2. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VRAX
Add Virax Biolabs Group Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VRAX